Search

Your search keyword '"Schmitt, Clemens"' showing total 744 results
Start Over Author "Schmitt, Clemens"
744 results on '"Schmitt, Clemens"'

9. Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy.

Author

Prasanna, Pataje G, Citrin, Deborah E, Hildesheim, Jeffrey, Ahmed, Mansoor M, Venkatachalam, Sundar, Riscuta, Gabriela, Xi, Dan, Zheng, Guangrong, Deursen, Jan van, Goronzy, Jorg, Kron, Stephen J, Anscher, Mitchell S, Sharpless, Norman E, Campisi, Judith, Brown, Stephen L, Niedernhofer, Laura J, O'Loghlen, Ana, Georgakilas, Alexandros G, Paris, Francois, Gius, David, Gewirtz, David A, Schmitt, Clemens A, Abazeed, Mohamed E, Kirkland, James L, Richmond, Ann, Romesser, Paul B, Lowe, Scott W, Gil, Jesus, Mendonca, Marc S, Burma, Sandeep, Zhou, Daohong, and Coleman, C Norman

Subjects
Cancer, Prevention, Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

Cellular senescence is an essential tumor suppressive mechanism that prevents the propagation of oncogenically activated, genetically unstable, and/or damaged cells. Induction of tumor cell senescence is also one of the underlying mechanisms by which cancer therapies exert antitumor activity. However, an increasing body of evidence from preclinical studies demonstrates that radiation and chemotherapy cause accumulation of senescent cells (SnCs) both in tumor and normal tissue. SnCs in tumors can, paradoxically, promote tumor relapse, metastasis, and resistance to therapy, in part, through expression of the senescence-associated secretory phenotype. In addition, SnCs in normal tissue can contribute to certain radiation- and chemotherapy-induced side effects. Because of its multiple roles, cellular senescence could serve as an important target in the fight against cancer. This commentary provides a summary of the discussion at the National Cancer Institute Workshop on Radiation, Senescence, and Cancer (August 10-11, 2020, National Cancer Institute, Bethesda, MD) regarding the current status of senescence research, heterogeneity of therapy-induced senescence, current status of senotherapeutics and molecular biomarkers, a concept of "one-two punch" cancer therapy (consisting of therapeutics to induce tumor cell senescence followed by selective clearance of SnCs), and its integration with personalized adaptive tumor therapy. It also identifies key knowledge gaps and outlines future directions in this emerging field to improve treatment outcomes for cancer patients.

Published
2021

10. Therapy-Induced Senescence: Opportunities to Improve Anti-Cancer Therapy

Author

Prasanna, Pataje G, Citrin, Deborah E, Hildesheim, Jeffrey, Ahmed, Mansoor M, Venkatachalam, Sundar, Riscuta, Gabriela, Xi, Dan, Zheng, Guangrong, van Deursen, Jan, Goronzy, Jorg, Kron, Stephen J, Anscher, Mitchell S, Sharpless, Norman E, Campisi, Judith, Brown, Stephen L, Niedernhofer, Laura J, O'Loghlen, Ana, Georgakilas, Alexandros G, Paris, Francois, Gius, David, Gewirtz, David A, Schmitt, Clemens A, Abazeed, Mohamed E, Kirkland, James L, Richmond, Ann, Romesser, Paul B, Lowe, Scott W, Gil, Jesus, Mendonca, Marc S, Burma, Sandeep, Zhou, Daohong, and Coleman, C Norman

Subjects
Cancer, Prevention, Good Health and Well Being, Biomarkers, Cellular Senescence, Humans, Neoplasms, Senescence-Associated Secretory Phenotype, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Cellular senescence is an essential tumor suppressive mechanism that prevents the propagation of oncogenically activated, genetically unstable, and/or damaged cells. Induction of tumor cell senescence is also one of the underlying mechanisms by which cancer therapies exert antitumor activity. However, an increasing body of evidence from preclinical studies demonstrates that radiation and chemotherapy cause accumulation of senescent cells (SnCs) both in tumor and normal tissue. SnCs in tumors can, paradoxically, promote tumor relapse, metastasis, and resistance to therapy, in part, through expression of the senescence-associated secretory phenotype. In addition, SnCs in normal tissue can contribute to certain radiation- and chemotherapy-induced side effects. Because of its multiple roles, cellular senescence could serve as an important target in the fight against cancer. This commentary provides a summary of the discussion at the National Cancer Institute Workshop on Radiation, Senescence, and Cancer (August 10-11, 2020, National Cancer Institute, Bethesda, MD) regarding the current status of senescence research, heterogeneity of therapy-induced senescence, current status of senotherapeutics and molecular biomarkers, a concept of "one-two punch" cancer therapy (consisting of therapeutics to induce tumor cell senescence followed by selective clearance of SnCs), and its integration with personalized adaptive tumor therapy. It also identifies key knowledge gaps and outlines future directions in this emerging field to improve treatment outcomes for cancer patients.

Published
2021

14. Design and Engineering of an Energy Maintenance Hub Superstructure

Author

Adam, Frank, Dierken, Peter, Aye, Moe Moe, Wittmann, Falk, Schmitt, Clemens, Cobzaru, Alexandru, di Prisco, Marco, Series Editor, Chen, Sheng-Hong, Series Editor, Vayas, Ioannis, Series Editor, Kumar Shukla, Sanjay, Series Editor, Sharma, Anuj, Series Editor, Kumar, Nagesh, Series Editor, Wang, Chien Ming, Series Editor, Piątek, Łukasz, editor, Lim, Soon Heng, editor, and de Graaf-van Dinther, Rutger, editor

Published
2022
Full Text
View/download PDF

16. The genomic and transcriptional landscape of primary central nervous system lymphoma

Author

Radke, Josefine, Ishaque, Naveed, Koll, Randi, Gu, Zuguang, Schumann, Elisa, Sieverling, Lina, Uhrig, Sebastian, Hübschmann, Daniel, Toprak, Umut H., López, Cristina, Hostench, Xavier Pastor, Borgoni, Simone, Juraeva, Dilafruz, Pritsch, Fabienne, Paramasivam, Nagarajan, Balasubramanian, Gnana Prakash, Schlesner, Matthias, Sahay, Shashwat, Weniger, Marc, Pehl, Debora, Radbruch, Helena, Osterloh, Anja, Korfel, Agnieszka, Misch, Martin, Onken, Julia, Faust, Katharina, Vajkoczy, Peter, Moskopp, Dag, Wang, Yawen, Jödicke, Andreas, Trümper, Lorenz, Anagnostopoulos, Ioannis, Lenze, Dido, Küppers, Ralf, Hummel, Michael, Schmitt, Clemens A., Wiestler, Otmar D., Wolf, Stephan, Unterberg, Andreas, Eils, Roland, Herold-Mende, Christel, Brors, Benedikt, Siebert, Reiner, Wiemann, Stefan, and Heppner, Frank L.

Published
2022
Full Text
View/download PDF

17. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors

Author

Bonifacius, Agnes, Lamottke, Britta, Tischer-Zimmermann, Sabine, Schultze- Florey, Rebecca, Goudeva, Lilia, Heuft, Hans-Gert, Arseniev, Lubomir, Beier, Rita, Beutel, Gernot, Cario, Gunnar, Frohlich, Birgit, Greil, Johann, Hansmann, Leo, Hasenkamp, Justin, Hofs, Michaela, Hundsdoerfer, Patrick, Jost, Edgar, Kafa, Kinan, Kriege, Oliver, Kroger, Nicolaus, Mathas, Stephan, Meisel, Roland, Nathrath, Michaela, Putkonen, Mervi, Ravens, Sarina, Reinhardt, Hans Christian, Sala, Elisa, Sauer, Martin G., Schmitt, Clemens, Schroers, Roland, Steckel, Nina Kristin, Trappe, Ralf Ulrich, Verbeek, Mareike, Wolff, Daniel, Blasczyk, Rainer, Eiz-Vesper, Britta, and Maecker-Kolhoff, Britta

Subjects
Cells -- Transplantation, Epstein-Barr virus diseases -- Complications and side effects, T cells -- Health aspects, Immunotherapy -- Methods, Lymphoproliferative disorders -- Care and treatment, Graft versus host reaction -- Care and treatment, Health care industry
Abstract

BACKGROUND. Adoptive transfer of EBV-specific T cells can restore specific immunity in immunocompromised patients with EBV-associated complications. METHODS. We provide results of a personalized T cell manufacturing program evaluating donor, patient, T cell product, and outcome data. Patient-tailored clinical-grade EBV-specific cytotoxic T lymphocyte (EBV-CTL) products from stem cell donors (SCDs), related third-party donors (TPDs), or unrelated TPDs from the allogeneic T cell donor registry (alloCELL) at Hannover Medical School were manufactured by immunomagnetic selection using a CliniMACS Plus or Prodigy device and the EBV PepTivators EBNA-1 and Select. Consecutive manufacturing processes were evaluated, and patient outcome and side effects were retrieved by retrospective chart analysis. RESULTS. Forty clinical-grade EBV-CTL products from SCDs, related TPDs, or unrelated TPDs were generated for 37 patients with refractory EBV infections or EBV-associated malignancies with and without a history of transplantation, within 5 days (median) after donor identification. Thirty-four patients received 1-14 EBV-CTL products (fresh and cryopreserved). EBV-CTL transfer led to a complete response in 20 of 29 patients who were evaluated for clinical response. No infusion-related toxicity was reported. EBV-specific T cells in patients' blood were detectable in 16 of 18 monitored patients (89%) after transfer, and their presence correlated with clinical response. CONCLUSION. Personalized clinical-grade manufacture of EBV-CTL products via immunomagnetic selection from SCDs, related TPDs, or unrelated TPDs in a timely manner is feasible. Overall, EBV-CTLs were clinically effective and well tolerated. Our data suggest EBV-CTL transfer as a promising therapeutic approach for immunocompromised patients with refractory EBV-associated diseases beyond HSCT, as well as patients with preexisting organ dysfunction. TRIAL REGISTRATION. Not applicable. FUNDING. This study was funded in part by the German Research Foundation (DFG, 158989968/SFB 900), the Deutsche Kinderkrebsstiftung (DKS 2013.09), Wilhelm-Sander-Stiftung (reference 2015.097.1), Ellen-Schmidt-Program of Hannover Medical School, and German Federal Ministry of Education and Research (reference 01E00802)., Introduction Morbidity and mortality in patients with hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) are frequently caused by graft rejection or graft-versus-host disease (GvHD) and increased by [...]

Published
2023
Full Text
View/download PDF

18. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma

Author

Wilke, Anne C., Doebele, Carmen, Zindel, Alena, Lee, Kwang Seok, Rieke, Sara A., Ceribelli, Michele, Comoglio, Federico, Phelan, James D., Wang, James Q., Pikman, Yana, Jahn, Dominique, Häupl, Björn, Schneider, Constanze, Scheich, Sebastian, Tosto, Frances A., Bohnenberger, Hanibal, Stauder, Philipp, Schnütgen, Frank, Slabicki, Mikolaj, Coulibaly, Zana A., Wolf, Sebastian, Bojarczuk, Kamil, Chapuy, Björn, Brandts, Christian H., Stroebel, Philipp, Lewis, Caroline A., Engelke, Michael, Xu, Xincheng, Kim, Hahn, Dang, Thanh Hung, Schmitz, Roland, Hodson, Daniel J., Stegmaier, Kimberly, Urlaub, Henning, Serve, Hubert, Schmitt, Clemens A., Kreuz, Fernando, Knittel, Gero, Rabinowitz, Joshua D., Reinhardt, Hans Christian, Vander Heiden, Matthew G., Thomas, Craig, Staudt, Louis M., Zenz, Thorsten, and Oellerich, Thomas

Published
2022
Full Text
View/download PDF

20. Supplementary Table S5 from Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer

Author

Bei, Yi, primary, Bramé, Luca, primary, Kirchner, Marieluise, primary, Fritsche-Guenther, Raphaela, primary, Kunz, Severine, primary, Bhattacharya, Animesh, primary, Rusu, Mara-Camelia, primary, Gürgen, Dennis, primary, Dubios, Frank P.B., primary, Köppke, Julia K.C., primary, Proba, Jutta, primary, Wittstruck, Nadine, primary, Sidorova, Olga Alexandra, primary, Chamorro González, Rocío, primary, Dorado Garcia, Heathcliff, primary, Brückner, Lotte, primary, Xu, Robin, primary, Giurgiu, Mădălina, primary, Rodriguez-Fos, Elias, primary, Yu, Qinghao, primary, Spanjaard, Bastiaan, primary, Koche, Richard P., primary, Schmitt, Clemens A., primary, Schulte, Johannes H., primary, Eggert, Angelika, primary, Haase, Kerstin, primary, Kirwan, Jennifer, primary, Hagemann, Anja I.H., primary, Mertins, Philipp, primary, Dörr, Jan R., primary, and Henssen, Anton G., primary

Published
2024
Full Text
View/download PDF

21. Supplementary Figures S1-S9 from Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer

Author

Bei, Yi, primary, Bramé, Luca, primary, Kirchner, Marieluise, primary, Fritsche-Guenther, Raphaela, primary, Kunz, Severine, primary, Bhattacharya, Animesh, primary, Rusu, Mara-Camelia, primary, Gürgen, Dennis, primary, Dubios, Frank P.B., primary, Köppke, Julia K.C., primary, Proba, Jutta, primary, Wittstruck, Nadine, primary, Sidorova, Olga Alexandra, primary, Chamorro González, Rocío, primary, Dorado Garcia, Heathcliff, primary, Brückner, Lotte, primary, Xu, Robin, primary, Giurgiu, Mădălina, primary, Rodriguez-Fos, Elias, primary, Yu, Qinghao, primary, Spanjaard, Bastiaan, primary, Koche, Richard P., primary, Schmitt, Clemens A., primary, Schulte, Johannes H., primary, Eggert, Angelika, primary, Haase, Kerstin, primary, Kirwan, Jennifer, primary, Hagemann, Anja I.H., primary, Mertins, Philipp, primary, Dörr, Jan R., primary, and Henssen, Anton G., primary

Published
2024
Full Text
View/download PDF

22. Data from Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer

Author

Bei, Yi, primary, Bramé, Luca, primary, Kirchner, Marieluise, primary, Fritsche-Guenther, Raphaela, primary, Kunz, Severine, primary, Bhattacharya, Animesh, primary, Rusu, Mara-Camelia, primary, Gürgen, Dennis, primary, Dubios, Frank P.B., primary, Köppke, Julia K.C., primary, Proba, Jutta, primary, Wittstruck, Nadine, primary, Sidorova, Olga Alexandra, primary, Chamorro González, Rocío, primary, Dorado Garcia, Heathcliff, primary, Brückner, Lotte, primary, Xu, Robin, primary, Giurgiu, Mădălina, primary, Rodriguez-Fos, Elias, primary, Yu, Qinghao, primary, Spanjaard, Bastiaan, primary, Koche, Richard P., primary, Schmitt, Clemens A., primary, Schulte, Johannes H., primary, Eggert, Angelika, primary, Haase, Kerstin, primary, Kirwan, Jennifer, primary, Hagemann, Anja I.H., primary, Mertins, Philipp, primary, Dörr, Jan R., primary, and Henssen, Anton G., primary

Published
2024
Full Text
View/download PDF

23. Figure 6 from Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer

Author

Bei, Yi, primary, Bramé, Luca, primary, Kirchner, Marieluise, primary, Fritsche-Guenther, Raphaela, primary, Kunz, Severine, primary, Bhattacharya, Animesh, primary, Rusu, Mara-Camelia, primary, Gürgen, Dennis, primary, Dubios, Frank P.B., primary, Köppke, Julia K.C., primary, Proba, Jutta, primary, Wittstruck, Nadine, primary, Sidorova, Olga Alexandra, primary, Chamorro González, Rocío, primary, Dorado Garcia, Heathcliff, primary, Brückner, Lotte, primary, Xu, Robin, primary, Giurgiu, Mădălina, primary, Rodriguez-Fos, Elias, primary, Yu, Qinghao, primary, Spanjaard, Bastiaan, primary, Koche, Richard P., primary, Schmitt, Clemens A., primary, Schulte, Johannes H., primary, Eggert, Angelika, primary, Haase, Kerstin, primary, Kirwan, Jennifer, primary, Hagemann, Anja I.H., primary, Mertins, Philipp, primary, Dörr, Jan R., primary, and Henssen, Anton G., primary

Published
2024
Full Text
View/download PDF

24. Figure 4 from Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer

Author

Bei, Yi, primary, Bramé, Luca, primary, Kirchner, Marieluise, primary, Fritsche-Guenther, Raphaela, primary, Kunz, Severine, primary, Bhattacharya, Animesh, primary, Rusu, Mara-Camelia, primary, Gürgen, Dennis, primary, Dubios, Frank P.B., primary, Köppke, Julia K.C., primary, Proba, Jutta, primary, Wittstruck, Nadine, primary, Sidorova, Olga Alexandra, primary, Chamorro González, Rocío, primary, Dorado Garcia, Heathcliff, primary, Brückner, Lotte, primary, Xu, Robin, primary, Giurgiu, Mădălina, primary, Rodriguez-Fos, Elias, primary, Yu, Qinghao, primary, Spanjaard, Bastiaan, primary, Koche, Richard P., primary, Schmitt, Clemens A., primary, Schulte, Johannes H., primary, Eggert, Angelika, primary, Haase, Kerstin, primary, Kirwan, Jennifer, primary, Hagemann, Anja I.H., primary, Mertins, Philipp, primary, Dörr, Jan R., primary, and Henssen, Anton G., primary

Published
2024
Full Text
View/download PDF

25. Figure 5 from Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer

Author

Bei, Yi, primary, Bramé, Luca, primary, Kirchner, Marieluise, primary, Fritsche-Guenther, Raphaela, primary, Kunz, Severine, primary, Bhattacharya, Animesh, primary, Rusu, Mara-Camelia, primary, Gürgen, Dennis, primary, Dubios, Frank P.B., primary, Köppke, Julia K.C., primary, Proba, Jutta, primary, Wittstruck, Nadine, primary, Sidorova, Olga Alexandra, primary, Chamorro González, Rocío, primary, Dorado Garcia, Heathcliff, primary, Brückner, Lotte, primary, Xu, Robin, primary, Giurgiu, Mădălina, primary, Rodriguez-Fos, Elias, primary, Yu, Qinghao, primary, Spanjaard, Bastiaan, primary, Koche, Richard P., primary, Schmitt, Clemens A., primary, Schulte, Johannes H., primary, Eggert, Angelika, primary, Haase, Kerstin, primary, Kirwan, Jennifer, primary, Hagemann, Anja I.H., primary, Mertins, Philipp, primary, Dörr, Jan R., primary, and Henssen, Anton G., primary

Published
2024
Full Text
View/download PDF

26. Figure 3 from Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer

Author

Bei, Yi, primary, Bramé, Luca, primary, Kirchner, Marieluise, primary, Fritsche-Guenther, Raphaela, primary, Kunz, Severine, primary, Bhattacharya, Animesh, primary, Rusu, Mara-Camelia, primary, Gürgen, Dennis, primary, Dubios, Frank P.B., primary, Köppke, Julia K.C., primary, Proba, Jutta, primary, Wittstruck, Nadine, primary, Sidorova, Olga Alexandra, primary, Chamorro González, Rocío, primary, Dorado Garcia, Heathcliff, primary, Brückner, Lotte, primary, Xu, Robin, primary, Giurgiu, Mădălina, primary, Rodriguez-Fos, Elias, primary, Yu, Qinghao, primary, Spanjaard, Bastiaan, primary, Koche, Richard P., primary, Schmitt, Clemens A., primary, Schulte, Johannes H., primary, Eggert, Angelika, primary, Haase, Kerstin, primary, Kirwan, Jennifer, primary, Hagemann, Anja I.H., primary, Mertins, Philipp, primary, Dörr, Jan R., primary, and Henssen, Anton G., primary

Published
2024
Full Text
View/download PDF

27. Figure 1 from Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer

Author

Bei, Yi, primary, Bramé, Luca, primary, Kirchner, Marieluise, primary, Fritsche-Guenther, Raphaela, primary, Kunz, Severine, primary, Bhattacharya, Animesh, primary, Rusu, Mara-Camelia, primary, Gürgen, Dennis, primary, Dubios, Frank P.B., primary, Köppke, Julia K.C., primary, Proba, Jutta, primary, Wittstruck, Nadine, primary, Sidorova, Olga Alexandra, primary, Chamorro González, Rocío, primary, Dorado Garcia, Heathcliff, primary, Brückner, Lotte, primary, Xu, Robin, primary, Giurgiu, Mădălina, primary, Rodriguez-Fos, Elias, primary, Yu, Qinghao, primary, Spanjaard, Bastiaan, primary, Koche, Richard P., primary, Schmitt, Clemens A., primary, Schulte, Johannes H., primary, Eggert, Angelika, primary, Haase, Kerstin, primary, Kirwan, Jennifer, primary, Hagemann, Anja I.H., primary, Mertins, Philipp, primary, Dörr, Jan R., primary, and Henssen, Anton G., primary

Published
2024
Full Text
View/download PDF

28. Figure 2 from Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer

Author

Bei, Yi, primary, Bramé, Luca, primary, Kirchner, Marieluise, primary, Fritsche-Guenther, Raphaela, primary, Kunz, Severine, primary, Bhattacharya, Animesh, primary, Rusu, Mara-Camelia, primary, Gürgen, Dennis, primary, Dubios, Frank P.B., primary, Köppke, Julia K.C., primary, Proba, Jutta, primary, Wittstruck, Nadine, primary, Sidorova, Olga Alexandra, primary, Chamorro González, Rocío, primary, Dorado Garcia, Heathcliff, primary, Brückner, Lotte, primary, Xu, Robin, primary, Giurgiu, Mădălina, primary, Rodriguez-Fos, Elias, primary, Yu, Qinghao, primary, Spanjaard, Bastiaan, primary, Koche, Richard P., primary, Schmitt, Clemens A., primary, Schulte, Johannes H., primary, Eggert, Angelika, primary, Haase, Kerstin, primary, Kirwan, Jennifer, primary, Hagemann, Anja I.H., primary, Mertins, Philipp, primary, Dörr, Jan R., primary, and Henssen, Anton G., primary

Published
2024
Full Text
View/download PDF

29. Virus-induced senescence is a driver and therapeutic target in COVID-19

Author

Lee, Soyoung, Yu, Yong, Trimpert, Jakob, Benthani, Fahad, Mairhofer, Mario, Richter-Pechanska, Paulina, Wyler, Emanuel, Belenki, Dimitri, Kaltenbrunner, Sabine, Pammer, Maria, Kausche, Lea, Firsching, Theresa C., Dietert, Kristina, Schotsaert, Michael, Martínez-Romero, Carles, Singh, Gagandeep, Kunz, Séverine, Niemeyer, Daniela, Ghanem, Riad, Salzer, Helmut J. F., Paar, Christian, Mülleder, Michael, Uccellini, Melissa, Michaelis, Edward G., Khan, Amjad, Lau, Andrea, Schönlein, Martin, Habringer, Anna, Tomasits, Josef, Adler, Julia M., Kimeswenger, Susanne, Gruber, Achim D., Hoetzenecker, Wolfram, Steinkellner, Herta, Purfürst, Bettina, Motz, Reinhard, Di Pierro, Francesco, Lamprecht, Bernd, Osterrieder, Nikolaus, Landthaler, Markus, Drosten, Christian, García-Sastre, Adolfo, Langer, Rupert, Ralser, Markus, Eils, Roland, Reimann, Maurice, Fan, Dorothy N. Y., and Schmitt, Clemens A.

Published
2021
Full Text
View/download PDF

30. QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross‐sectional analysis of the randomized AGMT 02 study.

Author

Ludwig, Heinz, Melchardt, Thomas, Schweitzer, Ilvy, Sormann, Siegfried, Schreder, Martin, Andel, Johannes, Hartmann, Bernd, Zojer, Niklas, Schöffmann, Laurenz, Gunsilius, Eberhard, Podar, Klaus, Egle, Alexander, Willenbacher, Wolfgang, Wöll, Ewald, Ruckser, Reinhard, Bozic, Boris, Krauth, Maria‐Theresa, Petzer, Andreas, Schmitt, Clemens, and Machherndl‐Spandl, Sigrid

Published
2024
Full Text
View/download PDF

31. Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple myeloma

Author

Ludwig, Heinz, primary, Melchardt, Thomas, additional, Sormann, Siegfried, additional, Schreder, Martin, additional, Andel, Johannes, additional, Hartmann, Bernd, additional, Tinchon, Christoph, additional, Zojer, Niklas, additional, Gunsilius, Eberhard, additional, Podar, Klaus, additional, Egle, Alexander, additional, Willenbacher, Wolfgang, additional, Wöll, Ewald, additional, Ruckser, Reinhard, additional, Bozic, Boris, additional, Krauth, Maria‐Theresa, additional, Petzer, Andreas, additional, Schmitt, Clemens, additional, Machherndl‐Spandl, Sigrid, additional, Agis, Hermine, additional, Fillitz, Michael, additional, Wang, Song‐Yau, additional, Zabernigg, August, additional, Knop, Stefan, additional, Paiva, Bruno, additional, and Greil, Richard, additional

Published
2024
Full Text
View/download PDF

32. Improved chronostratigraphy for the Messel Formation (Hesse, Germany) provides insight into early to middle Eocene climate variability

Author

Kaboth-Bahr, Stefanie, primary, Schmitt, Clemens, additional, Bauersachs, Thorsten, additional, Zeeden, Christian, additional, Wonik, Thomas, additional, Schandl, Jonas, additional, Lenz, Olaf, additional, Wedmann, Sonja, additional, Vasiliev, Iuliana, additional, Mulch, Andreas, additional, Lourens, Lucas, additional, Pross, Jörg, additional, and Bahr, André, additional

Published
2024
Full Text
View/download PDF

33. Passenger gene co-amplifications create collateral therapeutic vulnerabilities in cancer

Author

Bei, Yi, primary, Brame, Luca, additional, Kirchner, Marieluise, additional, Fritsche-Guenther, Raphaela, additional, Kunz, Severine, additional, Bhattacharya, Animesh, additional, Rusu, Mara-Camelia, additional, Gurgen, Dennis, additional, Dubois, Frank P.B., additional, Koppke, Julia K.C., additional, Proba, Jutta, additional, Wittstruck, Nadine, additional, Sidorova, Olga Alexandra., additional, Chamorro Gonzalez, Rocío, additional, Dorado Garcia, Heathcliff, additional, Bruckner, Lotte, additional, Xu, Robin, additional, Giurgiu, Madalina, additional, Rodriguez-Fos, Elias, additional, Yu, Qinghao, additional, Spanjaard, Bastiaan, additional, Koche, Richard P., additional, Schmitt, Clemens A., additional, Schulte, Johannes H., additional, Eggert, Angelika, additional, Haase, Kerstin, additional, Kirwan, Jennifer, additional, Hagemann, Anja IH., additional, Mertins, Philipp, additional, Dorr, Jan R., additional, and Henssen, Anton G., additional

Published
2024
Full Text
View/download PDF

37. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I

Author

Brägelmann, Johannes, Lorenz, Carina, Borchmann, Sven, Nishii, Kazuya, Wegner, Julia, Meder, Lydia, Ostendorp, Jenny, Ast, David F., Heimsoeth, Alena, Nakasuka, Takamasa, Hirabae, Atsuko, Okawa, Sachi, Dammert, Marcel A., Plenker, Dennis, Klein, Sebastian, Lohneis, Philipp, Gu, Jianing, Godfrey, Laura K., Forster, Jan, Trajkovic-Arsic, Marija, Zillinger, Thomas, Haarmann, Mareike, Quaas, Alexander, Lennartz, Stefanie, Schmiel, Marcel, D’Rozario, Joshua, Thomas, Emily S., Li, Henry, Schmitt, Clemens A., George, Julie, Thomas, Roman K., von Karstedt, Silvia, Hartmann, Gunther, Büttner, Reinhard, Ullrich, Roland T., Siveke, Jens T., Ohashi, Kadoaki, Schlee, Martin, and Sos, Martin L.

Published
2021
Full Text
View/download PDF

42. LncRNA MIR31HG fosters stemness malignant features of non-small cell lung cancer via H3K4me1- and H3K27Ace-mediated GLI2 expression

Author

Chen, Weiwei, primary, Wang, Fei, additional, Yu, Xinyuan, additional, Qi, Jingjing, additional, Dong, Hongliang, additional, Cui, Bingjie, additional, Zhang, Qian, additional, Wu, Yan, additional, An, Jiajia, additional, Ni, Na, additional, Liu, Cuilan, additional, Han, Yuchen, additional, Zhang, Shuo, additional, Schmitt, Clemens A., additional, Deng, Jiong, additional, Yu, Yong, additional, and Du, Jing, additional

Published
2023
Full Text
View/download PDF

44. Transcriptional repression of NFKBIA triggers constitutive IKK‐ and proteasome‐independent p65/RelA activation in senescence

Author

Kolesnichenko, Marina, Mikuda, Nadine, Höpken, Uta E, Kärgel, Eva, Uyar, Bora, Tufan, Ahmet Bugra, Milanovic, Maja, Sun, Wei, Krahn, Inge, Schleich, Kolja, von Hoff, Linda, Hinz, Michael, Willenbrock, Michael, Jungmann, Sabine, Akalin, Altuna, Lee, Soyoung, Schmidt‐Ullrich, Ruth, Schmitt, Clemens A, and Scheidereit, Claus

Published
2021
Full Text
View/download PDF

46. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT

Author

Pleyer, Lisa, primary, Vaisband, Marc, additional, Drost, Manuel, additional, Pfeilstöcker, Michael, additional, Stauder, Reinhard, additional, Heibl, Sonja, additional, Sill, Heinz, additional, Girschikofsky, Michael, additional, Stampfl‐Mattersberger, Margarete, additional, Pichler, Angelika, additional, Hartmann, Bernd, additional, Petzer, Andreas, additional, Schreder, Martin, additional, Schmitt, Clemens A., additional, Vallet, Sonia, additional, Melchardt, Thomas, additional, Zebisch, Armin, additional, Pichler, Petra, additional, Zaborsky, Nadja, additional, Machherndl‐Spandl, Sigrid, additional, Wolf, Dominik, additional, Keil, Felix, additional, Hasenauer, Jan, additional, Larcher‐Senn, Julian, additional, and Greil, Richard, additional

Published
2023
Full Text
View/download PDF

47. P943: OUTCOME ANALYSIS BY CYTOGENETIC RISK GROUP AFTER RANDOMIZATION TO KRD OR KTD FOLLOWED BY K MAINTENANCE OR CONTROL IN PATIENTS WITH NTE NDMM (AGMT MM-02)

Author

Ludwig, Heinz, primary, Melchardt, Thomas, additional, Sormann, Siegfried, additional, Schreder, Martin, additional, Andel, Johannes, additional, Hartmann, Bernd, additional, Tinchon, Christoph, additional, Zojer, Niklas, additional, Gunsilius, Eberhard, additional, Podar, Klaus, additional, Egle, Alexander, additional, Willenbacher, Wolfgang, additional, Woell, Ewald, additional, Ruckser, Reinhard, additional, Bozic, Boris, additional, Theresa Krauth, Maria, additional, Petzer, Andreas, additional, Schmitt, Clemens A., additional, Machherndl-Spandl, Sigrid, additional, Agis, Hermine, additional, Fillitz, Michael, additional, Wang, Song-Yau, additional, Knop, Stefan, additional, Paiva, Bruno, additional, and Greil, Richard, additional

Published
2023
Full Text
View/download PDF

48. Overall survival benefit of patients with biliary tract cancer receiving molecular profiling: a real-world multicenter retrospective cohort analysis

Author

Doleschal, Bernhard, primary, Taghizadeh, Hossein, additional, Webersinke, Gerald, additional, Piringer, Gudrun, additional, Schreil, Georg, additional, Decker, Jörn, additional, Aichberger, Karl J., additional, Kirchweger, Patrick, additional, Thaler, Josef, additional, Petzer, Andreas, additional, Schmitt, Clemens A., additional, Prager, Gerald, additional, and Rumpold, Holger, additional

Published
2023
Full Text
View/download PDF

49. P429: THERAPY-INDUCED SENESCENCE TRIGGERS UPREGULATION OF ANTIGEN PRESENTATION VIA PRC2 INHIBITION AND PROMOTES ANTI-TUMOUR IMMUNITY IN ACUTE MYELOID LEUKAEMIA

Author

Gilioli, Diego, primary, Fusco, Simona, additional, Tavella, Teresa, additional, Giannetti, Kety, additional, Conti, Anastasia, additional, Antonella, Santoro, additional, Carsana, Edoardo, additional, Beretta, Stefano, additional, Schönlein, Martin, additional, Gambacorta, Valentina, additional, Aletti, Federico, additional, Giovanni Carrabba, Matteo, additional, Bonini, Chiara, additional, Ciceri, Fabio, additional, Merelli, Ivan, additional, Vago, Luca, additional, Schmitt, Clemens A., additional, and DI Micco, Raffaella, additional

Published
2023
Full Text
View/download PDF

50. Initiation of acute graft-versus-host disease by angiogenesis

Author

Riesner, Katarina, Shi, Yu, Jacobi, Angela, Kräter, Martin, Kalupa, Martina, McGearey, Aleixandria, Mertlitz, Sarah, Cordes, Steffen, Schrezenmeier, Jens-Florian, Mengwasser, Jörg, Westphal, Sabine, Perez-Hernandez, Daniel, Schmitt, Clemens, Dittmar, Gunnar, Guck, Jochen, and Penack, Olaf

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results